Navigation Links
Portola Pharmaceuticals Initiates Phase II Trial of Betrixaban, its Novel Oral Factor Xa Inhibitor for Stroke Prevention in Atrial Fibrillation
Date:11/3/2008

SOUTH SAN FRANCISCO, Calif., Nov. 3 /PRNewswire/ -- Portola Pharmaceuticals, a biopharmaceutical company developing innovative drugs that provide significant advances in cardiovascular and inflammatory diseases, and cancer, today announced that it has begun patient enrollment in a large Phase II clinical trial of betrixaban, the Company's novel oral Factor Xa inhibitor anticoagulant, for stroke prevention in patients with atrial fibrillation (SPAF).

"This is a major milestone achievement to advance the first of our two highly differentiated Phase II product candidates that address the unmet needs of the more than 50 million patients worldwide requiring hospital or chronic antithrombotic therapy," said Charles Homcy, M.D., president and chief executive officer of Portola. "Betrixaban's unique profile has the promise to deliver reliable efficacy administered once-daily without the excess bleeding associated with other anticoagulants."

The Phase II trial, called EXPLORE Xa, is a multi-national, double-blind, dose-finding study that will enroll approximately 500 patients and assess three once-daily doses of betrixaban (40 mg, 60 mg, and 80 mg) administered for at least three months compared to dose-adjusted warfarin (given open label), the current standard of care, in patients with non-valvular atrial fibrillation. The goal of the study is to assess long-term safety and tolerability of betrixaban and provide key dosing information for Phase III studies. The Company expects to complete enrollment of this trial by the end of 2009.

Potential Best in Class Therapy

"We are thrilled to have the opportunity to evaluate what we believe is a truly unique anticoagulant in an exciting new class," said Stuart Connolly, M.D., director of the Division of Cardiology at McMaster University, Hamilton, Ontario, Canada, and principal investigator. "Because betrixaban may provide predictable anticoagulation combined with a lower risk of bleeding, and beca
'/>"/>

SOURCE Portola Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Portola Pharmaceuticals Names William Lis Vice President of Business Development and Commercial Operations
2. Vion Pharmaceuticals Pays Interest on 7.75% Convertible Senior Notes
3. China Biopharmaceuticals Holdings Announces Second Quarter 2007 Financial Results
4. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
5. XTL Biopharmaceuticals Announces Financial Results for the Six Months Ended June 30, 2007
6. Cadence Pharmaceuticals Reports Second Quarter 2007 Financial Results
7. Nabi Biopharmaceuticals to Present at Upcoming Industry Conferences
8. Anadys Pharmaceuticals Appoints Steve Worland, Ph.D. as President and Chief Executive Officer
9. Poniard Pharmaceuticals Announces Participation in Upcoming Conferences
10. NovaQuest Advances Virtual Development Model With Strategic Investment in TOPIGEN Pharmaceuticals
11. Drug Royalty Corporation (DRC) Announces Acquisition Regarding PEG-INTRON(R) From Enzon Pharmaceuticals, Inc. (ENZN)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/17/2014)... -- Hussey Copper , a leader in copper ... announces Gilmour Academy Ice Arena,s conversion of more than ... touch surface to help protect against bacteria.  MD-Cu 29 ... kills greater than 99.9% of MRSA, E-coli and other ... , Innovative Gilmour Academy prepares ...
(Date:9/17/2014)... LAKE FOREST, California , 17 de ... BB: CYRX) ("la compañía"), principal proveedor mundial ... industria de las ciencias de la vida, ... una compañía de logística global con sede ... a su base de clientes Europa en ...
(Date:9/17/2014)... September 17, 2014 The Pistoia ... to lowering the barriers to innovation in life ... appointment of Carmen Nitsche as Executive Director Business ... expand its global reach. , Carmen joins the ... President, Corporate Development. At Accelrys, she managed various ...
(Date:9/16/2014)... DIEGO , Sept. 16, 2014  Biocom, the ... life science community, recognizes the 9 th Annual ... the value of IT technologies in improving our health ... is one of the world,s most vibrant ... EHRs to mobile health applications to genomic testing to ...
Breaking Biology Technology:Innovative Gilmour Academy Ice Arena changes more than 200 fixtures to Hussey Copper's MD-Cu29 antimicrobial copper to help protect against bacteria 2Innovative Gilmour Academy Ice Arena changes more than 200 fixtures to Hussey Copper's MD-Cu29 antimicrobial copper to help protect against bacteria 3Cryoport contrata a Broekman Group para mejorar su apoyo operativo y logístico en Europa 2Cryoport contrata a Broekman Group para mejorar su apoyo operativo y logístico en Europa 3Cryoport contrata a Broekman Group para mejorar su apoyo operativo y logístico en Europa 4Cryoport contrata a Broekman Group para mejorar su apoyo operativo y logístico en Europa 5Pistoia Alliance Expands Business Development with Appointment of Carmen Nitsche 2Biocom Recognizes National Health IT Week 2
... NanoSmart™ Pharmaceuticals, Inc., a California corporation developing novel biopharmaceuticals, ... Notice of Allowance for a US patent on its ... taken an approach to targeting tumors that is different ... the company. "While most of cancer research has focused ...
... Applied Precision, along with Indiana University, are ... DeltaVision|OMX imaging system in the Light Microscopy Imaging ... is a ground-breaking, three dimensional, super-resolution microscopy system ... traditional light microscopy. This super-resolution capability is especially ...
... Results -- HARBIN, China, Aug. 16 /PRNewswire-Asia-FirstCall/ -- ... ... ... are keyed by longUrl, so we need to grab the first one. for (var r in ...
Cached Biology Technology:NanoSmart™ Pharmaceuticals, Inc. Receives Patent Allowance for Tumor Targeting Platform Technology 2Applied Precision Installs New DeltaVision|OMX® Super-Resolution Imaging System in the Light Microscopy Imaging Center at Indiana University 2Weikang Bio-Technology Reports Second Quarter 2010 Financial Results 2Weikang Bio-Technology Reports Second Quarter 2010 Financial Results 3Weikang Bio-Technology Reports Second Quarter 2010 Financial Results 4Weikang Bio-Technology Reports Second Quarter 2010 Financial Results 5Weikang Bio-Technology Reports Second Quarter 2010 Financial Results 6Weikang Bio-Technology Reports Second Quarter 2010 Financial Results 7Weikang Bio-Technology Reports Second Quarter 2010 Financial Results 8Weikang Bio-Technology Reports Second Quarter 2010 Financial Results 9Weikang Bio-Technology Reports Second Quarter 2010 Financial Results 10Weikang Bio-Technology Reports Second Quarter 2010 Financial Results 11Weikang Bio-Technology Reports Second Quarter 2010 Financial Results 12Weikang Bio-Technology Reports Second Quarter 2010 Financial Results 13Weikang Bio-Technology Reports Second Quarter 2010 Financial Results 14
(Date:9/16/2014)... tree species has its own bacterial identity. That,s the ... other institutions who studied the genetic fingerprints of bacteria ... island. , "This study demonstrates for the first time ... different ecological strategies possess very different microbial communities on ... former postdoctoral researcher in the UO,s Institute of Ecology ...
(Date:9/16/2014)... interaction between viruses, bacteria, and their environment is ... collaboration between Matthew Sullivan, associate professor in the ... Biology and Steven Hallam from the University of ... are drivers of nutrient and energy cycles that ... is changing, so are the environments these bacteria ...
(Date:9/16/2014)... a peacock show its extravagant, colorful tail feathers in ... have used a special camera developed by an engineer ... female northern swordtail fish choose their mates based on ... of Texas at Austin used a bioinspired polarization camera ... science & engineering at Washington University, to make the ...
Breaking Biology News(10 mins):Microbiome research shows each tree species has a unique bacterial identity 2New research decodes virus-host interactions in ocean dead zones 2New research decodes virus-host interactions in ocean dead zones 3Camera developed at WUSTL sheds light on mate choice of swordtail fish 2
... Our body,s activity levels fall and rise to the beat ... functions, from sleeping and feeding patterns to the energy available ... is set by light, the pacemakers in peripheral organs are ... Now, researchers at the Salk Institute for Biological ...
... Conference on Molecular Targets and Cancer Therapeutics is the ... therapies. This year,s conference brings together delegates from all ... target selection and the impact of new discoveries in ... plan your coverage of the conference, the program schedule ...
... long been recognized as essential to the advancement of ... knowledge in collaborative settings has been studied for some ... in collaborations established and maintained through virtual organizations. ... of New York (CCNY) is studying how virtual organizations, ...
Cached Biology News:The food-energy cellular connection revealed 2The food-energy cellular connection revealed 3CCNY researchers study scientific collaboration in age of internet 2
dithiothreitol (DTT) Reactive Dyes and Chemicals Thiol-Reactive Dyes, Haptens and Quenchers Reducing Agents...
GRADIENT MAKER, 30 ML, 1 EA. Category: Protein Vertical Instruments....
Recombinant Rat Leptin, CF...
actin from rabbit muscle Cell Biology Cytoskeletal Probes Actin and Actin Probes...
Biology Products: